Key Highlights
- ImmunityBio shares rise following UAE’s comprehensive ANKTIVA authorization
- Regulatory clearance covers complete spectrum of adult bladder cancer cases
- UAE authorization includes metastatic lung cancer following treatment resistance
- Clinical data shows 71% complete response rate in bladder cancer patients
- ANKTIVA regulatory footprint now extends to 34 nations globally
Shares of ImmunityBio (IBRX) climbed 5.86% during pre-market hours to $7.23 following a 2.01% decline to $6.83 at the previous close. The recovery came after the Emirates health authority granted authorization for ANKTIVA in treating both bladder and lung cancers with restricted therapeutic alternatives. This regulatory milestone represents the company’s most comprehensive approval to date and significantly extends the treatment’s global market presence.
Dual Cancer Indication Approval Granted by UAE Regulators
The Emirates Drug Establishment has authorized ANKTIVA in combination with BCG for adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer. The regulatory clearance encompasses carcinoma in situ cases, mixed tumor presentations, and papillary-only disease presentations lacking carcinoma in situ. This authorization represents the inaugural approval addressing the complete BCG-unresponsive NMIBC disease spectrum within a single regulatory framework.
Additionally, regulators approved ANKTIVA combined with immune checkpoint inhibitors for treating metastatic non-small cell lung cancer. Treatment eligibility requires documented disease advancement following conventional checkpoint therapy or chemotherapy combination regimens. Patients presenting actionable genetic mutations must demonstrate progression after approved targeted therapies before qualifying for the ANKTIVA treatment protocol.
The UAE joins four other regulatory jurisdictions in authorizing ANKTIVA distribution. According to ImmunityBio, the therapy currently maintains regulatory authorization spanning 34 nations through various international approvals. This expanded regulatory decision bolsters the company’s commercial presence in two challenging oncology sectors characterized by substantial unmet medical requirements.
Clinical Evidence Validates Comprehensive Bladder Cancer Application
The bladder cancer authorization stems from findings in the multicenter QUILT-3.032 registrational trial. Within the carcinoma in situ patient cohort, the ANKTIVA plus BCG regimen produced a 71% complete response rate. Responding patients demonstrated a median response duration of 26.6 months throughout extended trial monitoring.
Data showed 66% of responding patients sustained complete response status at the 12-month mark. By 24 months, 42% continued demonstrating complete response following treatment administration. These outcomes validated therapeutic application across patients presenting with carcinoma in situ and associated papillary tumor formations.
The papillary-only patient cohort achieved a 58.2% disease-free survival rate at 12 months. Within this patient subset, median disease-free survival extended to 25.3 months. Notably, 83.1% of participants avoided cystectomy at 36 months, maintaining a critical organ-preservation therapeutic pathway.
Positive Lung Cancer Data Broadens Treatment Portfolio
The lung cancer regulatory clearance derives from Phase 2 QUILT-3.055 trial findings. Researchers enrolled 79 participants experiencing disease progression following prior checkpoint inhibitor therapy. Median overall survival across the complete study cohort reached 14.6 months post-treatment initiation.
Participants presenting elevated lymphocyte levels achieved median overall survival of 16.2 months. This subgroup comprised 77% of trial enrollees. Their survival outcomes surpassed the 11.8-month median observed among participants with reduced lymphocyte counts.
Treatment generated common injection site reactions, chills, fatigue, fever, and nausea. The bladder cancer trial predominantly documented Grade 1 or Grade 2 treatment-associated adverse events. ImmunityBio secures an expanded regulatory foundation while progressing ANKTIVA’s international launch strategy across supplementary territories.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
